Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia
Katharine J. Bar, Pamela A. Shaw, Grace Choi, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 24
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
Jonathon W. Senefeld, Massimo Franchini, Carlo Mengoli, et al.
JAMA Network Open (2023) Vol. 6, Iss. 1, pp. e2250647-e2250647
Open Access | Times Cited: 125
COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
Daniele Focosi, Massimo Franchini, Liise-anne Pirofski, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 3
Open Access | Times Cited: 89
Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma
Lise J Estcourt, Claudia S. Cohn, Monica B. Pagano, et al.
Annals of Internal Medicine (2022) Vol. 175, Iss. 9, pp. 1310-1321
Open Access | Times Cited: 63
Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19
Andrea B. Troxel, Eva Petkova, Keith Goldfeld, et al.
JAMA Network Open (2022) Vol. 5, Iss. 1, pp. e2147331-e2147331
Open Access | Times Cited: 45
Convalescent plasma for people with COVID-19: a living systematic review
Claire Iannizzi, Khai Li Chai, Vanessa Piechotta, et al.
Cochrane library (2023) Vol. 2023, Iss. 2
Open Access | Times Cited: 31
Convalescent plasma for people with COVID-19: a living systematic review
Claire Iannizzi, Khai Li Chai, Vanessa Piechotta, et al.
Cochrane library (2023) Vol. 2024, Iss. 2
Closed Access | Times Cited: 29
Mortality Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis
Jonathon W. Senefeld, Ellen K. Gorman, Patrick W. Johnson, et al.
Mayo Clinic Proceedings Innovations Quality & Outcomes (2023) Vol. 7, Iss. 5, pp. 499-513
Open Access | Times Cited: 28
Safety and Efficacy of Convalescent Plasma Combined with Other Pharmaceutical Agents for Treatment of COVID-19 in Hospitalized Patients: A Systematic Review and Meta-Analysis
Massimo Franchini, Daniele Focosi, Mario Cruciani, et al.
Diseases (2024) Vol. 12, Iss. 3, pp. 41-41
Open Access | Times Cited: 8
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 31
Convalescent Plasma Therapy for COVID-19: A Systematic Review and Meta-Analysis on Randomized Controlled Trials
Charalampos Filippatos, Ioannis Ntanasis‐Stathopoulos, Kalliopi Sekeri, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 765-765
Open Access | Times Cited: 16
Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial
Karine Lacombe, Thomas Hueso, Raphaël Porcher, et al.
BMJ Medicine (2023) Vol. 2, Iss. 1, pp. e000427-e000427
Open Access | Times Cited: 16
Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis
Jiawen Deng, Kiyan Heybati, Harikrishnaa Ba Ramaraju, et al.
Infection (2022) Vol. 51, Iss. 1, pp. 21-35
Open Access | Times Cited: 26
Neutrophil Activity and Extracellular Matrix Degradation: Drivers of Lung Tissue Destruction in Fatal COVID-19 Cases and Implications for Long COVID
Teluguakula Narasaraju, Indira Neeli, Sheila Criswell, et al.
Biomolecules (2024) Vol. 14, Iss. 2, pp. 236-236
Open Access | Times Cited: 4
Decrease in Angiotensin-Converting Enzyme activity but not concentration in plasma/lungs in COVID-19 patients offers clues for diagnosis/treatment
Henry Daniell, Smruti K. Nair, Yao Shi, et al.
Molecular Therapy — Methods & Clinical Development (2022) Vol. 26, pp. 266-278
Open Access | Times Cited: 21
Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy
Jonathan D. Herman, Chuangqi Wang, John S. Burke, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 11, pp. 100811-100811
Open Access | Times Cited: 19
High-Throughput Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March and August 2020
Shuting Zhang, Peijun Ma, Marek Orzechowski, et al.
mBio (2023) Vol. 14, Iss. 2
Open Access | Times Cited: 10
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial
Han-Sol Park, Anna Yin, Caelan Barranta, et al.
JCI Insight (2024) Vol. 9, Iss. 8
Open Access | Times Cited: 3
Association between COVID-19 convalescent plasma antibody levels and COVID-19 outcomes stratified by clinical status at presentation
Hyung Park, Chang Yu, Liise‐anne Pirofski, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Early administration of COVID‐19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy
Artur Belov, Yin Huang, Carlos H. Villa, et al.
American Journal of Hematology (2022) Vol. 97, Iss. 6, pp. 770-779
Open Access | Times Cited: 15
Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study
Luther A. Bartelt, Alena J. Markmann, Bridget Nelson, et al.
mBio (2022) Vol. 13, Iss. 5
Open Access | Times Cited: 12
Managing blood supplies during natural disasters, humanitarian emergencies, and pandemics: lessons learned from COVID-19
Tayler A. Van Denakker, Arwa Z. Al‐Riyami, Rita Feghali, et al.
Expert Review of Hematology (2023) Vol. 16, Iss. 7, pp. 501-514
Closed Access | Times Cited: 7
Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI)
Alice Tung Wan Song, Vanderson Rocha, Alfredo Mendrone, et al.
The Lancet Regional Health - Americas (2022) Vol. 10, pp. 100216-100216
Open Access | Times Cited: 11
Immune Plasma for the Treatment of COVID-19: Lessons Learned so far
Hubert Schrezenmeier, Simone Hoffmann, Henrike Hofmann, et al.
Hämostaseologie (2023) Vol. 43, Iss. 01, pp. 067-074
Open Access | Times Cited: 5
COVID-19 convalescent plasma boosts early antibody titer and does not influence the adaptive immune response
John F. McDyer, Mahzad Azimpouran, Valerie Durkalski‐Mauldin, et al.
JCI Insight (2023) Vol. 8, Iss. 8
Open Access | Times Cited: 5
Convalescent plasma and all-cause mortality of COVID-19 patients: systematic review and meta-analysis
Nora Mihalek, Dragana Radovanović, Otto Barak, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top